Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 13, 2021
Reporting Period: Event date of September 13, 2021
Business Context: The Company, an emerging growth company incorporated in Nevada, entered into a material definitive agreement regarding new corporate headquarters or office space.
Key Financial Metrics
This filing reports a specific contractual obligation rather than periodic financial performance. Consequently, revenue, profit, cash flow, margins, and liquidity metrics are not disclosed in this document.
| Metric | Value |
|---|---|
| Monthly Rent | $9,839.33 |
| Lease Term | 64 months |
| Premises Size | 5,165 square feet |
| Location | Boca Raton, Florida |
Material Changes
The primary material change is the execution of a new lease agreement with Crocker Mizner Park IV, Ltd. This creates a direct financial obligation for the Company. The lease term is set to commence on the earlier of October 1, 2021, or ten days after the premises are ready for occupancy. The rent is subject to yearly increments as defined in the agreement.
Outlook, Risks, and Management Commentary
Management Commentary: The filing confirms the Company's expansion or relocation to a 6th-floor suite in the Mizner Park Office Tower. No forward-looking financial guidance or strategic outlook beyond the lease terms is provided in this specific report.
Risks and Contingencies: The Company assumes a fixed monthly rental obligation with scheduled increases. The filing notes that the summary of terms is qualified by the full Lease Agreement document.
Key Facts for Investor Verification
- Verify the total committed lease liability over the 64-month term, including projected yearly rent increments.
- Confirm the exact commencement date of the lease to determine the start of cash outflows.
- Review the full text of Exhibit 10.1 (Lease Agreement) for details on escalation clauses, termination rights, and additional operating expenses not captured in the base rent.
- Assess the impact of this new fixed cost on the Company's current cash runway, given the lack of revenue disclosure in this filing.